IBM to Tackle Post-Genomic Computing Challenges in MDS Proteomics Alliance | GenomeWeb

The strategic alliance with MDS Proteomics is a “major milestone” in IBM’s aggressive push to gain a foothold in the life sciences computing market, said Anne-Marie Derouault, director of business development and marketing at IBM.

Under the terms of the alliance, IBM will be the preferred provider of hardware, software and services to MDS and the two companies will collaborate on the development of BIND (biomolecular interaction network database), a publicly available database of molecular-level protein interactions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.